BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 27, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/24 cls
BioSante (BPA) Oppenheimer Kevin DeGeeter New Buy 1% $5.86
DeGeeter set a $9 target. He believes BPA's LibiGel testosterone to treat hypoactive sexual desire disorder (HSDD) has potential sales of >$500M, which may be monetized over the next 12-18 months through a commercial partnership or sale of the company. The transdermal gel is in Phase III testing.
Cephalon (CEPH) Jefferies David Windley Price target Buy 8% $73.78
Windley raised his target to $90 from $88 after CEPH said it will acquire North American rights to market Amrix from ECR. He believes...

Read the full 628 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >